• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

The Top 5 Biosimilar Articles for the Week of February 8

Video

Here are the top 5 biosimilar articles for the week of February 8, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of February 8, 2021.

Number 5: An 80-week observational studysuggests a non-medical switch from infliximab to SB2 is “a feasible option” for patients with inflammatory bowel diseases.

Number 4: A patient in a hospital outpatient setting was 42% less likely to receive a filgrastim biosimilar than a patient in an office setting, but 73% more likely to receive an infliximab biosimilar, according to a large, cross-sectional study.

Number 3: Biosimilar competition took a big chunk of revenue from Roche's aging blockbusters in 2020, and the company is banking on its newer medicines to drive fresh revenue growth.

Number 2: Celltrion Healthcare has received Canadian authorization to market a subcutaneous formulation of the infliximab biosimilar Remsima (Remsima SC; CT-P13).

Number 1: During its 2020 earnings call, Amgen described how a double-edged biosimilars sword has worked for and against the company's profit margin.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Ha Kung Wong, JD.
Here are the top 5 biosimilar articles for the week of April 15, 2024.
The Top 5 Biosimilars Articles for the Week of April 8, 2024.
Ha Kung Wong, JD.
Related Content
© 2024 MJH Life Sciences

All rights reserved.